查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1932030

超音波导引乳房切片市场（依手术类型、产品、病灶类型、影像技术和最终用途划分），全球预测，2026-2032年

Ultrasound-Guided Breast Biopsy Market by Procedure Type, Product, Lesion Type, Imaging Technology, End Use - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年超音波引导乳房切片市场价值为 1.8125 亿美元，预计到 2026 年将成长至 1.9965 亿美元，预计到 2032 年将达到 3.5834 亿美元，复合年增长率为 10.22%。

关键市场统计数据
基准年 2025 1.8125亿美元
预计年份：2026年 1.9965亿美元
预测年份 2032 3.5834亿美元
复合年增长率 (%) 10.22%

本文简要概述了超音波引导乳房切片的战略重要性，重点关注其临床整合、工作流程影响以及相关人员的优先事项。

随着微创诊断和精准介入治疗的重要性日益凸显，乳房医学领域正迅速发展。超音波引导下乳房切片已成为一项基础性技术，它使临床医生能够透过即时成像识别可疑病灶，从而减少与侵入性操作相关的患者併发症，并简化诊断流程。随着影像精度的提高和操作效率的提升，这项技术现已成为多学科乳房诊疗的核心组成部分，有助于加快临床决策，并与病理工作流程更紧密地衔接。

影像技术、设备易用性、流程工作流程和监管协调的进步如何重塑组织诊断的实践模式和采购重点

技术融合、流程标准化和不断变化的临床需求正在推动该领域发生多项变革性转变。高解析度即时成像技术已从静态灰阶显示器发展到先进的3D和4D渲染，从而提高了病灶特征的辨识度和针头的可视化效果。同时，携带式和手持式系统也呈现出明显的趋势，这些系统分散了影像导引切片检查的进行地点，使得手术可以在门诊手术中心和诊断诊所等传统医院手术室外进行。

评估近期美国关税调整如何推动医疗设备生态系统的供应链重组、筹资策略转变以及製造在地化进程。

贸易和关税政策的变化将对医疗设备供应链和筹资策略产生重大影响，美国近期在2025年前的政策调整也不例外。关税调整将影响进口系统、组件和耗材的成本基础，从而改变依赖全整合系统和一次性手术用品的医院和门诊中心的采购趋势。为此，采购团队正在重新评估其筹资策略，实现供应商多元化，并提高国内製造和区域分销中心的重要性，以降低关税波动带来的风险。

深度分割分析揭示了手术类型、最终使用环境、产品类型、病变分类和影像方式如何影响临床选择和采购决策。

了解市场区隔的细微差别对于准确指导产品开发、商业化和临床实施工作至关重要。依手术类型分析，临床医生通常会根据病灶特征和诊断目标，在粗针穿刺活检、细针穿刺切片检查和真空辅助活检之间进行选择；对于粗针穿刺活检，他们还会进一步选择14G、16G和18G等不同规格的针头，以平衡组织获取量和侵入性。最终用户环境决定了操作需求和采购标准：门诊手术中心优先考虑便携性、吞吐量和易于消毒；诊断中心重视影像品质和与报告系统的工作流程整合；而医院则优先考虑企业级可维护性、互通性和全面的维护协议。

区域医疗保健系统、采购政策和基础设施优先事项如何影响美洲、欧洲、中东和非洲以及亚太地区的采用模式和供应商策略

区域趋势影响超音波引导乳房切片的普及模式、报销环境、监管要求和供应链结构。在美洲，对门诊诊疗模式的高度重视以及对照护现场技术的投入，影响着临床应用，促使携带式成像系统和简化的耗材（一次性耗材）更受青睐。明确的监管政策和成熟的临床路径支持新技术的快速应用。同时，采购趋势倾向于在成本效益和维护支援能力之间取得平衡，确保不会中断侦测能力。

医疗器材创新者、耗材製造商和服务供应商的竞争格局和策略行动将影响医疗保健机构的采纳、检验和采购优先事项。

该领域的竞争动态由诊断成像技术创新者、针头和耗材製造商以及提供培训、维护和整合服务的服务型公司之间的相互作用所决定。成功的企业能够将临床级成像性能与符合人体工学的设备设计以及完善的耗材生态系统相结合，从而简化采购和库存管理。那些将临床医生对针头可见性、组织采集效率和操作人体工学的回馈纳入研发蓝图的企业，更有可能获得更强的临床验证并加快产品推广应用。

为製造商和医疗系统领导者提供可操作的策略重点，以加强产品系列、强化供应链、提升临床医生技能，并使其商业模式适应临床环境。

产业领导者应优先考虑一系列务实且注重营运的倡议，以平衡临床价值与商业性可行性。首先，投资涵盖整个手术流程的产品系列——从高清晰度成像系统到可靠的针头设计以及精简的配件——确保客户采购到可互操作的解决方案，而非互不相容的零散组件。在产品开发的同时，进行量化手术结果、检体合格和安全性指标的临床证据项目，将有助于加强与医院董事会和门诊中心管理人员的价值对话。

结合临床医生访谈、技术文件审查和监管分析的严格三角测量调查方法，可以得出检验的营运和策略见解，而无需猜测。

我们的研究途径结合了定性研究和二手分析（包括对同行评审文献、临床实践指南、监管文件、医疗设备註册资讯和已发布的技术规范的分析），以建立强有力的证据基础。我们的主要研究包括对放射科医师、病理科主任、采购负责人和医疗设备工程师进行结构化访谈，以了解实际临床环境中的挑战、应用驱动因素和未满足的需求。我们深入了解了临床决策标准，包括针头规格选择、影像偏好和耗材生命週期管理。

整合策略要务，重点关注综合产品解决方案、临床医生教育和健全的采购体系，以确保患者能够获得诊疗服务并改善诊断结果。

超音波引导下乳房切片在诊断流程中发挥至关重要的作用，它以微创精准的方式连接了影像检测和病理诊断。该技术的未来发展将受到以下因素的影响：影像技术和穿刺针设计的进步；受贸易政策驱动的采购和供应链策略的务实转变；以及製造商提供满足不同临床环境需求的整合解决方案的能力。随着医疗模式的不断分散化以及对快速、高品质诊断需求的成长，能够整合临床证据、产品互通性和可靠采购管道的相关人员将更有能力创造价值。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章超音波引导乳房切片市场（依手术类型划分）

  • 核心针穿刺切片
    • 14G
    • 16G
    • 18G
  • 细针穿刺切片检查
  • 真空辅助针吸切片

第九章超音波引导乳房切片市场（依产品划分）

  • 配件
  • 针
    • 一次性的
    • 可重复使用的
  • 系统
    • 手持式
    • 桌面型

第十章 依病变类型分類的超音波导引乳房切片市场

  • 良性
  • 恶性

第十一章超音波引导乳房切片市场（依影像技术划分）

  • 3D和4D
  • 即时2D

第十二章 依最终用途分類的超音波引导乳房切片市场

  • 门诊手术中心
  • 诊断中心
  • 医院

第十三章超音波引导乳房切片市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章超音波引导乳房切片市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国超音波引导乳房切片市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国超音波引导乳房切片市场

第十七章：中国超音波引导乳房切片市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ARGON MEDICAL DEVICES, Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Canon Medical Systems Corporation
  • Cardinal Health, Inc.
  • Cook Medical, Inc.
  • Danaher Corporation
  • Esaote SpA
  • Exact Sciences Corp.
  • F. Hoffmann-La Roche Ltd
  • FUJIFILM Holdings Corporation
  • GE HealthCare Technologies Inc.
  • Hologic, Inc.
  • Izi Medical Products, LLC
  • Konica Minolta Healthcare Americas, Inc.
  • Koninklijke Philips NV
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Mindray Medical International Limited
  • Olympus Corporation
  • QIAGEN NV
  • Samsung Electronics Co., Ltd.
  • Siemens Healthineers AG
  • Sterylab SRL
  • Stryker Corporation
Product Code: MRR-7B550E008E32

The Ultrasound-Guided Breast Biopsy Market was valued at USD 181.25 million in 2025 and is projected to grow to USD 199.65 million in 2026, with a CAGR of 10.22%, reaching USD 358.34 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 181.25 million
Estimated Year [2026] USD 199.65 million
Forecast Year [2032] USD 358.34 million
CAGR (%) 10.22%

A concise orientation to the strategic importance of ultrasound-guided breast biopsy highlighting clinical integration, workflow impacts, and stakeholder priorities

The landscape of breast healthcare has progressed rapidly with increased emphasis on minimally invasive diagnostics and precision-guided interventions. Ultrasound-guided breast biopsy has become a cornerstone technique, offering clinicians the ability to localize suspicious lesions with real-time imaging, reduce patient morbidity associated with more invasive procedures, and streamline diagnostic pathways. As imaging fidelity improves and procedural ergonomics evolve, the modality is now central to multidisciplinary breast care, enabling faster clinical decision-making and tighter integration with pathology workflows.

Clinicians and health system leaders are recalibrating care pathways to leverage ultrasound-guided biopsy for both palpable and non-palpable lesions identified through screening or symptomatic presentation. From an operational perspective, the technique supports throughput in ambulatory settings and can reduce downstream diagnostic delays. Consequently, stakeholders across device manufacturing, procurement, and clinical leadership are prioritizing investments in imaging systems, needle technologies, and procedural accessories that optimize tissue yield while minimizing complications. This introduction establishes a foundation for the subsequent sections that analyze technological shifts, regulatory and trade influences, segmentation nuances, regional dynamics, competitive behaviors, and practical recommendations for leaders aiming to strengthen their position within this evolving domain.

How advances in imaging, device ergonomics, procedural workflows, and regulatory alignment are reshaping practice patterns and procurement priorities in tissue diagnostics

The field is undergoing several transformative shifts driven by technological convergence, procedural standardization, and evolving clinical expectations. High-resolution real-time imaging has advanced from static grayscale displays to more sophisticated three-dimensional and four-dimensional renderings that enhance lesion characterization and needle visualization. Concurrently, there is a clear movement toward portable and handheld systems that decentralize access to image-guided biopsy, enabling procedures in ambulatory surgical centers and diagnostic clinics outside traditional hospital suites.

Procedurally, the adoption curve has been influenced by refinements in core needle design, vacuum-assisted technology, and a renewed focus on disposable consumables that simplify sterilization protocols and reduce cross-contamination risk. These device-level changes align with broader care delivery trends that emphasize same-day diagnostics, reduced patient throughput times, and enhanced patient experience. Moreover, the intersection of imaging software enhancements-such as improved needle-tracking algorithms and integrated reporting tools-with telemedicine-enabled consults has reconfigured pre-procedural planning and post-procedural follow-up, facilitating more collaborative care between radiology, pathology, and surgical teams.

From a regulatory and reimbursement standpoint, incremental updates in clinical guidelines and coding frameworks have encouraged adoption by clarifying best practices and aligning incentives with less invasive diagnostic approaches. Meanwhile, supply chain dynamics and manufacturing innovation are driving incremental cost efficiencies, yet demand for higher-performing systems continues to create pressure for product differentiation. Taken together, these shifts are reorienting priorities for clinical champions and procurement professionals who must balance capital expenditure, consumable lifecycle costs, and the imperative to deliver high-quality, patient-centered care.

Assessing how recent United States tariff adjustments are prompting supply chain reconfiguration, procurement strategy shifts, and manufacturing localization efforts across device ecosystems

Policy changes in trade and tariff regimes can exert material influence on medical device supply chains and procurement strategies, and recent tariff developments in the United States for 2025 are no exception. Tariff adjustments affect the cost basis for imported systems, components, and consumables, thereby altering purchasing dynamics for hospitals and ambulatory centers that rely on both fully integrated systems and disposable procedural items. Procurement teams, in response, are revisiting sourcing strategies, seeking to diversify suppliers, and increasing emphasis on domestic manufacturing or regional distribution hubs to mitigate exposure to tariff volatility.

Operationally, the cumulative effects of tariffs manifest in longer lead times as supply chains pivot and as manufacturers reassess their production footprints. Contracts for service and maintenance, which frequently include imported spare parts or specialized accessories, must be renegotiated to reflect revised landed costs and potential duty mitigation strategies. In addition, research and development teams may accelerate initiatives to localize component sourcing or redesign products to reduce reliance on tariffed inputs. Regulatory compliance and documentation burdens can also intensify as vendors manage customs classifications and demonstrate traceability for clinical devices.

Clinicians and administrators alike must therefore adapt procurement frameworks to preserve clinical quality while managing financial impact. This includes embedding tariff sensitivity into contract modeling and prioritizing supplier partnerships that offer flexible manufacturing, nearshoring capabilities, or established distribution channels within tariff-favored jurisdictions. Ultimately, while tariffs do not change the clinical value proposition of ultrasound-guided biopsy, they do compel a strategic response across sourcing, contracting, and capital planning processes to sustain service delivery and maintain procedural access.

Deep segmentation insights revealing how procedure types, end-use environments, product architectures, lesion classifications, and imaging modalities determine clinical and procurement choices

A nuanced understanding of market segments is essential for targeting product development, commercialization, and clinical adoption efforts. When procedures are disaggregated by type, clinicians often choose between core needle biopsy, fine needle aspiration, and vacuum-assisted approaches according to lesion characteristics and diagnostic objectives, with core needle biopsy further refined by gauge selection such as 14G, 16G, and 18G to balance tissue yield against invasiveness. End-use settings shape operational requirements and purchase criteria: ambulatory surgical centers prioritize portability, throughput, and ease of sterilization; diagnostic centers value image quality and workflow integration with reporting systems; and hospitals prioritize enterprise serviceability, interoperability, and comprehensive maintenance contracts.

Product-level considerations influence procurement pathways and clinical preferences. Accessories must align with procedural workflows to minimize setup time and maintain sterility, needles are evaluated on performance with distinctions between disposable and reusable options that affect lifecycle cost and infection control practices, and imaging systems are categorized by form factor with handheld devices emphasizing mobility and tabletop systems emphasizing advanced imaging capabilities and integration with ancillary diagnostic tools. Lesion type drives clinical decision-making, where benign presentations often call for conservative sampling protocols and malignant-suspect lesions demand higher-yield strategies and closer coordination with pathology services. Imaging technology choices also play a critical role; the adoption of 3D and 4D modalities enhances spatial visualization and lesion mapping, while real-time 2D imaging remains a workhorse for many point-of-care biopsy procedures due to its responsiveness and established clinical workflows.

Taken together, these segmentation lenses inform the priorities of manufacturers and providers. Product development must anticipate variations in gauge and device ergonomics, commercial teams must tailor value propositions to ambulatory, diagnostic, and hospital buyers, and clinical educators must design training programs that align with the imaging technology mix and lesion-specific sampling strategies. This alignment ensures that innovations translate into improved clinical outcomes and smoother operational adoption across diverse care settings.

How regional healthcare systems, procurement policies, and infrastructure priorities in the Americas, EMEA, and Asia-Pacific shape adoption patterns and supplier strategies

Regional dynamics shape adoption patterns, reimbursement environments, regulatory expectations, and supply chain architectures for ultrasound-guided breast biopsy. In the Americas, clinical adoption is influenced by a strong emphasis on outpatient care models and investments in point-of-care diagnostics, which favor portable imaging systems and streamlined disposable consumables. Regulatory clarity and well-established clinical pathways support rapid integration of new device features, while procurement tends to balance cost-effectiveness with service and support capabilities that maintain uninterrupted procedural capacity.

Across Europe, the Middle East and Africa, heterogeneous regulatory frameworks and variable access to advanced imaging infrastructure create a mosaic of adoption rates and clinical practices. In many Western European markets, centralized pathology networks and robust hospital systems support the uptake of higher-end tabletop systems and integrated reporting solutions, whereas in parts of the Middle East and Africa, priorities often tilt toward cost-effective, ruggedized systems and consumables that are compatible with varied clinical settings. Regional procurement policies and public health investment strategies additionally influence how quickly new procedural technologies are adopted.

In the Asia-Pacific region, the combination of expanding screening programs, investments in diagnostic capacity, and a growing middle-class patient base has accelerated demand for both handheld systems that facilitate decentralized care and sophisticated tabletop platforms in tertiary centers. Local manufacturing and regional distribution networks are increasingly important in this geography, shaping how suppliers position their portfolios and service offerings. Across all regions, interoperability with digital health records, compatibility with teleconsultation frameworks, and the availability of training and technical support are critical determinants of sustained adoption and scale-up of ultrasound-guided biopsy services.

Competitive profile and strategic behaviors of device innovators, consumable manufacturers, and service providers driving adoption, validation, and procurement preference across care settings

Competitive dynamics in this space are defined by the interplay between imaging innovators, needle and consumable manufacturers, and service-oriented companies that deliver training, maintenance, and integration services. Organizations that succeed combine clinical-grade imaging performance with ergonomic device footprints and robust consumable ecosystems that simplify procurement and inventory management. Companies that align their R&D roadmaps with clinician feedback on needle visibility, tissue capture efficiency, and procedural ergonomics tend to secure stronger clinical endorsement and faster uptake.

In addition to product excellence, market leaders invest in professional education and evidence generation to demonstrate procedural safety and diagnostic concordance with core pathology outcomes. Strategic partnerships with clinical networks, diagnostic centers, and ambulatory surgical providers help scale adoption through preference formation and shared protocols. Service capabilities, including predictable maintenance schedules, responsive parts distribution, and remote diagnostic support for imaging systems, serve as differentiators for large institutional buyers concerned with uptime and total cost of ownership.

Emerging entrants often compete on niche innovations such as AI-enabled image enhancement, compact system form factors for point-of-care settings, or single-use needle designs that address infection control imperatives. These entrants can catalyze incumbents to accelerate incremental product improvements or to pursue collaborations that extend their ecosystems. Ultimately, the most resilient companies will be those that pair technological differentiation with pragmatic commercialization strategies that address the specific needs of ambulatory centers, diagnostic clinics, and hospital systems alike.

Actionable strategic priorities for manufacturers and health system leaders to enhance product portfolios, fortify supply chains, accelerate clinician competency, and align commercial models with care settings

Industry leaders should prioritize a set of pragmatic, operationally focused actions that align clinical value with commercial viability. First, invest in product portfolios that address the full procedural continuum-from high-visibility imaging systems to reliable needle designs and streamlined accessories-so that customers can procure interoperable solutions rather than disparate components. Alongside product development, clinical evidence programs that quantify procedural outcomes, sample adequacy, and safety profiles will strengthen value conversations with hospital committees and ambulatory center administrators.

Second, strengthen supply chain resilience through supplier diversification, nearshoring where feasible, and contractual mechanisms that share risk related to tariff-driven cost fluctuations. This will reduce exposure to sudden cost shifts and preserve service continuity. Third, expand training and support infrastructures to accelerate competency across care settings; targeted simulation curricula and modular training for handheld versus tabletop imaging workflows can reduce variability in sample quality and patient experience. Fourth, tailor commercial models to end-use needs, offering bundled service and consumable agreements for high-volume ambulatory centers while providing enterprise-grade maintenance and integration packages for hospitals. Finally, embrace digital enablement-integrating reporting, needle-tracking enhancements, and teleconsultation capabilities to embed these procedures into broader diagnostic pathways and to create stickier clinical relationships.

By implementing these actions, organizations can better translate technological capability into sustained clinical adoption and operational efficiency, positioning themselves to meet the nuanced demands of diversified care delivery environments.

A rigorous triangulated methodology combining clinician interviews, technical document review, and regulatory analysis to derive validated operational and strategic insights without speculative sizing

The research approach combined primary qualitative engagements with secondary analysis of peer-reviewed literature, clinical practice guidelines, regulatory documents, device registries, and publicly available technical specifications to create a robust evidence base. Primary inputs included structured interviews with practicing radiologists, pathology leads, procurement officers, and device engineers to capture real-world procedural challenges, adoption drivers, and unmet needs. These interviews provided granular insights into clinical decision criteria such as needle gauge selection, imaging preferences, and consumable lifecycle concerns.

Secondary research corroborated clinical perspectives by examining published studies on diagnostic accuracy, procedure-related complications, and imaging system performance metrics. In addition, regulatory and standards guidance was reviewed to map compliance considerations relevant to device design and labeling. The method emphasized triangulation: qualitative findings were validated against literature and technical datasheets to ensure consistency. Geographical coverage was achieved by incorporating inputs from diverse healthcare systems to reflect regional procurement behaviors and infrastructure constraints. Finally, synthesis prioritized actionable implications for stakeholders while consciously avoiding speculative market sizing, focusing instead on observable trends, operational impacts, and strategic options that decision-makers can act upon.

Synthesis of strategic imperatives emphasizing integrated product solutions, clinician education, and resilient procurement to secure procedural access and improve diagnostic outcomes

Ultrasound-guided breast biopsy occupies a pivotal role in the diagnostic pathway, bridging imaging detection and pathologic diagnosis with minimally invasive precision. The modality's future will be shaped by technological refinements in imaging and needle design, by pragmatic shifts in procurement and supply chain strategies driven in part by trade policy, and by the ability of manufacturers to deliver integrated solutions that meet the needs of diverse clinical settings. As care models continue to decentralize and the demand for rapid, high-quality diagnostics grows, stakeholders who align clinical evidence, product interoperability, and resilient sourcing will be best positioned to deliver value.

Sustained progress will depend on collaborative efforts among device developers, clinical champions, and health system leaders to translate innovation into routine practice. This includes investing in training, clarifying procedural protocols across lesion types and settings, and maintaining agile procurement strategies that can adapt to regulatory and tariff developments. By focusing on these pragmatic levers, organizations can protect procedural access and enhance patient outcomes while navigating an evolving commercial and policy landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ultrasound-Guided Breast Biopsy Market, by Procedure Type

  • 8.1. Core Needle
    • 8.1.1. 14G
    • 8.1.2. 16G
    • 8.1.3. 18G
  • 8.2. Fine Needle Aspiration
  • 8.3. Vacuum-Assisted Needle

9. Ultrasound-Guided Breast Biopsy Market, by Product

  • 9.1. Accessories
  • 9.2. Needles
    • 9.2.1. Disposable
    • 9.2.2. Reusable
  • 9.3. Systems
    • 9.3.1. Handheld
    • 9.3.2. Tabletop

10. Ultrasound-Guided Breast Biopsy Market, by Lesion Type

  • 10.1. Benign
  • 10.2. Malignant

11. Ultrasound-Guided Breast Biopsy Market, by Imaging Technology

  • 11.1. 3D And 4D
  • 11.2. Real-Time 2D

12. Ultrasound-Guided Breast Biopsy Market, by End Use

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Centers
  • 12.3. Hospitals

13. Ultrasound-Guided Breast Biopsy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Ultrasound-Guided Breast Biopsy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Ultrasound-Guided Breast Biopsy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Ultrasound-Guided Breast Biopsy Market

17. China Ultrasound-Guided Breast Biopsy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. ARGON MEDICAL DEVICES, Inc.
  • 18.6. B. Braun Melsungen AG
  • 18.7. Becton, Dickinson and Company
  • 18.8. Canon Medical Systems Corporation
  • 18.9. Cardinal Health, Inc.
  • 18.10. Cook Medical, Inc.
  • 18.11. Danaher Corporation
  • 18.12. Esaote S.p.A.
  • 18.13. Exact Sciences Corp.
  • 18.14. F. Hoffmann-La Roche Ltd
  • 18.15. FUJIFILM Holdings Corporation
  • 18.16. GE HealthCare Technologies Inc.
  • 18.17. Hologic, Inc.
  • 18.18. Izi Medical Products, LLC
  • 18.19. Konica Minolta Healthcare Americas, Inc.
  • 18.20. Koninklijke Philips N.V.
  • 18.21. Medtronic plc
  • 18.22. Merit Medical Systems, Inc.
  • 18.23. Mindray Medical International Limited
  • 18.24. Olympus Corporation
  • 18.25. QIAGEN N.V.
  • 18.26. Samsung Electronics Co., Ltd.
  • 18.27. Siemens Healthineers AG
  • 18.28. Sterylab S.R.L.
  • 18.29. Stryker Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 14G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 14G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 14G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 16G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 16G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 16G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 18G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 18G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 18G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY VACUUM-ASSISTED NEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY VACUUM-ASSISTED NEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY VACUUM-ASSISTED NEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY DISPOSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY DISPOSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY DISPOSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY REUSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY REUSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY REUSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY HANDHELD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY HANDHELD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY HANDHELD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY TABLETOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY TABLETOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY TABLETOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY BENIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY BENIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY BENIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY MALIGNANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY MALIGNANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY MALIGNANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 3D AND 4D, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 3D AND 4D, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY 3D AND 4D, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY REAL-TIME 2D, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY REAL-TIME 2D, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY REAL-TIME 2D, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 157. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 184. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 185. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 193. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 194. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA ULTRASOUND-GUIDED BREAST BIOPSY MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)